2-(甲基氨基)-1-(1-吡咯烷)-1-乙酮盐酸盐 | 144685-61-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(甲基氨基)-1-(1-吡咯烷)-1-乙酮盐酸盐
• 英文名称: (methylamino)acetylpyrrolidne
• 英文别名: 2-(Methylamino)-1-(pyrrolidin-1-yl)ethanone；2-(methylamino)-1-pyrrolidin-1-ylethanone
• CAS: 144685-61-0
• 化学式: C₇H₁₄N₂O
• mdl: MFCD07690488
• 分子量: 142.201
• InChiKey: ZCPADTVDGNXMOD-UHFFFAOYSA-N

物化性质

• 沸点：
  255.6±23.0 °C(Predicted)
• 密度：
  1.042±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-溴-2-丁烯酸甲酯 、 2-(甲基氨基)-1-(1-吡咯烷)-1-乙酮盐酸盐 在 lithium diisopropyl amide 作用下， 生成
  参考文献：
  名称：

  Unusual Diastereofacial Selectivity in the Michael Addition Reactions of Lithiated 2-Aminoacetates and -acetamides to α,β-Unsaturated Carbonyl Compounds

  摘要：

  在锂化氨基乙酸酯和-乙酰胺与α,β-不饱和羰基受体的迈克尔加成反应中，观察到了不同寻常的非对映选择性。锂化（甲基氨基）乙酸酯和-乙酰胺分别显示出相反的反选择性和同选择性，而锂化（二烷基氨基）乙酸酯和-乙酰胺都具有高度的同选择性。

  DOI：

  10.1246/cl.1992.1801

文献信息

• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057916A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及式1的取代4-吡啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途，包含这些化合物的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY
  申请人：BYLOCK Lars Anders

  公开号：US20130236468A1

  公开（公告）日：2013-09-12

  The present invention relates to a combination comprising compounds of formula (I): wherein R 1 to R 3 , A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.

  本发明涉及一种组合物，包括式（I）的化合物： 其中R1至R3，A，X和n如本文所定义，并且另外包括一种活性剂。本发明还涉及包括这些组合物的药物组合物，以及使用这些组合物治疗各种疾病和疾病的方法。
• PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3939577A1

  公开（公告）日：2022-01-19

  The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

  该发明涉及根据权利要求1的药物组合物，包括一种葡萄糖吡喃基取代苯衍生物与一种适用于治疗或预防从以下选定的一种或多种疾病的DPP IV抑制剂的组合物，所述疾病包括1型糖尿病、2型糖尿病、糖耐量受损和高血糖。此外，本发明涉及预防或治疗代谢紊乱及相关疾病的方法。
• [EN] COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE CYCLOPHILINES ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2017173048A1

  公开（公告）日：2017-10-05

  The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin- related disorders.

  本发明涉及化合物及其药用可接受的组合物，用作环肽酶的抑制剂，以及用于治疗与环肽酶相关的疾病。
• [EN] NOVEL VIRAL REPLICATION INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE RÉPLICATION VIRALE
  申请人：UNIV LEUVEN KATH

  公开号：WO2011015641A1

  公开（公告）日：2011-02-10

  The present invention relates to a series of novel compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having antiviral activity.

  本发明涉及一系列具有抗病毒活性的新化合物，更具体地说是具有抑制HIV（人类免疫缺陷病毒）复制的特性。该发明还涉及制备这些化合物的方法，以及在这些合成步骤中使用的新中间体。该发明还涉及包含这些化合物作为活性成分的有效量的药物组合物。本发明进一步涉及将这些化合物用作药物或用于制造对患有病毒感染，特别是HIV感染的动物进行治疗的药物。本发明还涉及通过给动物投予这些化合物的治疗量，可选择地与具有抗病毒活性的一个或多个其他药物结合的方法来治疗动物的病毒感染。